Stock Market & Financial Investment News

News Breaks February 1, 2013 15:35 EDT GILD Gilead March volatility low as shares trade near record high into Q4 Gilead February call option implied volatility is at 32, March and April is at 26; compared to its 26-week average of 28 according to Track Data, suggesting decreasing price movement after the expected release of Q4 results on February 4. News For GILD From The Last 14 Days Check below for free stories on GILD the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 17, 2013 16:00 EDT GILD Options Update; June 17, 2013 Subscribe for More Information 06:25 EDT GILD Gilead reports interim Phase 2 data for Idelalisib Gilead announced interim results from a single-arm, open-label Phase 2 study evaluating idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma that is refractory to rituximab and to alkylating-agent-containing chemotherapy. Previously, this has been a largely unstudied population for which there is significant unmet medical need for effective therapy. In the study, single-agent treatment with idelalisib achieved an overall response rate of 53.6%, with a median duration of response at this interim analysis of 11.9 months. The most common Grade ≥3 adverse event was diarrhea . Grade ≥3 transaminase elevations were reported via central laboratory testing in 13% of patients; Grade ≥3 neutropenia occurred in 26% of patients. Sixteen percent of patients discontinued due to adverse events. June 13, 2013 10:05 EDT GILD On The Fly: Analyst Upgrade Summary Subscribe for More Information 07:33 EDT GILD Gilead upgraded to Buy from Hold at Argus Subscribe for More Information June 10, 2013 07:40 EDT GILD Leerink's biotech analyst holds analyst/industry conference call on ASCO Subscribe for More Information June 7, 2013 17:21 EDT GILD Gilead announces U.S. FDA priority review designation for Sofosbuvir Subscribe for More Information June 6, 2013 09:07 EDT GILD Gilead Sofosbuvir likely to be granted priority review, says RBC Capital Subscribe for More Information 08:27 EDT GILD Bernstein's biotech analysts hold an analyst/industry conference call Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.